Bayer CEO says faces 78 Trasylol lawsuits in U.S.
Fri Apr 25, 8:50 AM ET
"We are not aware of any lawsuit outside the United States," Werner Wenning told a shareholders' meeting.
Bayer in November temporarily suspended global marketing of Trasylol after preliminary results from a Canadian study linked its use to a higher risk of kidney damage and death.
It said it would vigorously defend itself.
At the meeting, Wenning also said the market environment for its plastics unit could improve next year. Bayer expected lower profit from the unit this year.
Bayer shares rose 4.9 percent to 56.32 euros at 1200 GMT, outpacing a 1.6 percent gain in the German blue-chip DAX index after it published forecast-beating results on Thursday.
(Reporting by Frank Siebelt; Editing by David Holmes)
( What's this? )
-
Refinance $300,000 for Only $965/Month
$300,000 Mortgage for only $965/month. Save $1,000's - No obligation.www.HomeLoanHelpLine.com
-
Refinance and Save $1,000S
$150,000 Mortgage for $483/month. Compare up to 4 free quotes.www.pickamortgage.com
-
Car Insurance Quotes Online
Compare auto insurance quotes from top companies online.www.insurance.com
Health Video
» All news video
Yahoo! News Topic Pages
Get in-depth coverage on exercise and fitness and health care with new topic pages.
Elsewhere on the Web
- ABC News: FDA Warns of Drug's Birth Defect Risk
- ABC News: Adopted vs. Biological: Which Kid Wins?
- Time.com: Do Consumers Understand Drug Ads?
Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.